Jury awards Centocor $1.7B in patent case against Abbott - Memphis Business Journal:

burwellmitubaes1369.blogspot.com
An Abbott spokesman said the companywill appeal. Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritistreatment Remicade, and had sued Abbottt over Abbott’s arthritis drug, Humira. Both are so-calle anti-TNF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusivre licensee of the whichis co-owned by . Centocor President Kim Taylodrsaid “the jury recognized our valuable intellectual property, finding our patent both valid and infringed.
We will continue to assert intellectual property rights for ourimmunologyt therapies, as they offer significant advances in treatment for patientsa with a number of immune mediated inflammatorty diseases.” Abbott spokesman Scott E. Stoffe l said, “We are disappointed in this verdict, and we are confident in the meritse of our case and that we will prevaiplon appeal. “The evidence clearlhy established that Humira was the first ofits fully-human anti-TNF antibody medicine,” Stoffel said. “JNJ’x anti-TNF antibody medication, is partially made from mouse DNA. JNJ did not launch a fully-humam product until April 2009.
In only when Humira was nearing its approvalo in 2002 did JNJ amend the patent at issude in this litigation to claim that it haddiscoverex fully-human antibodies in 1994. JNJ acknowledge at trial that it did not starf working ona fully-human antibody until 1997 — two yearz after Abbott discovered Humira and one year afterd Abbott filed its paten t applications for Humira.”